Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea

Clinical Microbiology and Infection

Volumn 17, Issue 8, 2011, Pages 1155-1159

  Kim, J Y ^a,b   Kim, E J ^a   Choi, J Y ^a   Kwon, O K ^a   Kim, G J ^a   Choi, S Y ^b   Kim, S S ^a  

^a Korea National Institute of Health   (South Korea)

^b Korea University   (South Korea)

Author keywords

Genetic variation; HIV 1; Integrase inhibitor; Polymorphism; Resistant mutation

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; DRUG EFFICACY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KOREA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79960662891     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03392.x     Document Type: Article

References (23)

1. HSIUNG GD. Perspectives on retroviruses and the etiologic agent of AIDS. Yale J Biol Med 1987; 60: 505-514.
2. UNAIDS and WHO (2007) AIDS epidemic update. 2008. Available at:.
3. Gazzard B, Bernard AJ, Boffito M et al. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2006; 7: 487-503.
4. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25years after the discovery of HIV. Int J Antimicrob Agents 2009; 33: 307-320.
5. Telenti A, Aubert V, Spertini F. Individualising HIV treatment-pharmacogenetics and immunogenetics. Lancet 2002; 359: 722-723.
6. Katzman M, Katz RA. Substrate recognition by retroviral integrases. Adv Virus Res 1999; 52: 371-395.
7. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991; 67: 1211-1221.
8. Cahn P, Sued O. Raltegravir: a new antiretroviral class for salvage therapy. Lancet 2007; 369: 1235-1236.
9. DeJesus E, Berger D, Markowitz M et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatmentexperienced patients. J Acquir Immune Defic Syndr 2006; 43: 1-5.
10. Cooper D, Gatell J, Rockstroh J et al. 48-week results from BENCHMRK-1, a phase III study of raltegravir in patients faiing ART with triple-class resistant HIV-1 [abstract 788/2008] In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA.
11. Steigbigel R, Kumar P, Eron J et al. 48-week results from BENCHMRK-2, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV [abstract 789/2008]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA.
12. Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2006; 2: 125-133.
13. Choi JY, Kim EJ, Park YK, Lee JS, Kim SS. National survey for drug-resistant variants in newly diagnosed antiretroviral drug-naive patients with HIV/AIDS in South Korea: 1999-2005. J Acquir Immune Defic Syndr 2008; 3: 237-242.
14. Van Laethem K, Schrooten Y, Covens K et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods 2008; 153: 176-181.
15. Reinke R, Steffen NR, Robinson WE Jr. Natural selection results in conservation of HIV-1 integrase activity despite sequence variability. AIDS 2001; 15: 823-830.
16. King PJ, Robinson WE Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol 1998; 72: 8420-8424.
17. Malet I, Soulie C, Tchertanov L et al. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol 2008; 80: 754-761.
18. Rhee SY, Liu TF, Kiuchi M et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008; 7: 5.
19. Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 1984; 226: 172-174.
20. Richard E. Myers, Deenan Pillay analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol 2008; 82: 9228-9235.
21. de la Carriere LC, Paulous S, Clavel F, Mammano F. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J Virol 1999; 73: 3455-3459.
22. Nakahara K, Wakasa-Morimoto C, Kobayashi M et al. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res 2008; 81: 141-146.
23. van Hal SJ, Herring B, Deris Z, Wang B, Kaksena NK, Dwyer DE. HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology 2009; 6: 12.